Compare Cytokinetics Inc (CYTK) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Invesco NASDAQ 100 ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 13.2× Cytokinetics Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| CYTK | QQQM | |
|---|---|---|
Market Cap | $8.62B | $113.40B |
Volume | 2,594,626 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $312.76 |
52-Week Low | $54.76 | $229.87 |
Typical Hold Time | 19 Days | 54 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
QQQM trades at $307.85, down 1.33% today, while maintaining a bullish technical outlook with strong moving average support. The Invesco NASDAQ 100 ETF continues to benefit from institutional accumulation, with QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show the ETF trading near key resistance at $309, with support established at $305 and $303 levels. The fund's 0.15% expense ratio provides a cost advantage over similar NASDAQ-100 tracking products.
QQQM offers efficient exposure to NASDAQ-100 growth stocks with lower fees, though concentration in technology sectors presents volatility risks. Institutional buying signals confidence in the ETF's long-term prospects despite recent market fluctuations. Investors should monitor technology sector performance and interest rate sensitivity as key drivers of future returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
